Abeona Therapeutics (ABEO) FCF Margin (2011 - 2026)

Abeona Therapeutics' FCF Margin history runs 13 years deep, the most recent figure standing at 237.83% for Q1 2026.

• In Q1 2026, FCF Margin changed N/A year-over-year to 237.83%; the TTM figure through Mar 2026 stood at 545.99% (changed N/A YoY), while the FY2025 annual figure was 1323.21%, changed N/A from the prior year.
• FCF Margin for Q1 2026 stood at 237.83%, down from 218.01% in the prior quarter.
• The five-year high for FCF Margin was 218.01% in Q4 2025, with the low at 20985.29% in Q4 2022.
• The 4-year median for FCF Margin is 901.3% (2022), against an average of 4524.12%.
• Peak annual rise in FCF Margin reached 60721 bps in 2023, while the deepest fall reached 60721 bps in 2023.
• Abeona Therapeutics' FCF Margin stood at 20985.29% in 2022, then jumped by 99 bps to 294.09% in 2023, then climbed by 26 bps to 218.01% in 2025, then decreased by 9 bps to 237.83% in 2026.
• Business Quant data shows ABEO's FCF Margin at 237.83% in Q1 2026, 218.01% in Q4 2025, and 5046.75% in Q2 2025.